AIMS: Chondroblastoma is a rare, locally aggressive bone tumour that causes osteolytic destruction at the epiphyseal end of the affected bone. It is possible that tumour cells may stimulate osteoclastogenesis and osteolytic destruction through the production of receptor activator of NF-kappaB ligand (RANKL), which is a key molecule essential for regulating osteoclast formation and activity. Therefore, the expression of RANKL at both the mRNA and the protein level was investigated in chondroblastoma tumour tissue obtained from patients. METHODS: The expression of RANKL gene transcripts was analysed by the reverse transcription-polymerase chain reaction (RT-PCR), and the cellular localisation of RANKL mRNA and protein was demonstrated by means of in situ hybridisation and immunohistochemistry. RESULTS: RT-PCR analysis indicated that RANKL mRNA was present in all chondroblastoma specimens and normal cancellous bone samples, but not in normal articular cartilage and chondrosarcoma tissues. In contrast, gene transcripts of osteoprotegerin (OPG), the decoy receptor of RANKL, were detected in all types of tissues. The chondroid origin of neoplastic mononuclear cells in chondroblastoma was confirmed by positive S-100 immunohistochemical staining. Both RANKL mRNA and protein were exclusively expressed in these neoplastic mononuclear cells. CONCLUSIONS: These findings suggest that RANKL may be involved in the tumour cell induced recruitment of osteoclast-like cells and consequent osteolytic bone destruction in chondroblastoma.
AIMS: Chondroblastoma is a rare, locally aggressive bone tumour that causes osteolytic destruction at the epiphyseal end of the affected bone. It is possible that tumour cells may stimulate osteoclastogenesis and osteolytic destruction through the production of receptor activator of NF-kappaB ligand (RANKL), which is a key molecule essential for regulating osteoclast formation and activity. Therefore, the expression of RANKL at both the mRNA and the protein level was investigated in chondroblastoma tumour tissue obtained from patients. METHODS: The expression of RANKL gene transcripts was analysed by the reverse transcription-polymerase chain reaction (RT-PCR), and the cellular localisation of RANKL mRNA and protein was demonstrated by means of in situ hybridisation and immunohistochemistry. RESULTS: RT-PCR analysis indicated that RANKL mRNA was present in all chondroblastoma specimens and normal cancellous bone samples, but not in normal articular cartilage and chondrosarcoma tissues. In contrast, gene transcripts of osteoprotegerin (OPG), the decoy receptor of RANKL, were detected in all types of tissues. The chondroid origin of neoplastic mononuclear cells in chondroblastoma was confirmed by positive S-100 immunohistochemical staining. Both RANKL mRNA and protein were exclusively expressed in these neoplastic mononuclear cells. CONCLUSIONS: These findings suggest that RANKL may be involved in the tumour cell induced recruitment of osteoclast-like cells and consequent osteolytic bone destruction in chondroblastoma.
Authors: W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle Journal: Cell Date: 1997-04-18 Impact factor: 41.582
Authors: H Hsu; D L Lacey; C R Dunstan; I Solovyev; A Colombero; E Timms; H L Tan; G Elliott; M J Kelley; I Sarosi; L Wang; X Z Xia; R Elliott; L Chiu; T Black; S Scully; C Capparelli; S Morony; G Shimamoto; M B Bass; W J Boyle Journal: Proc Natl Acad Sci U S A Date: 1999-03-30 Impact factor: 11.205
Authors: G J Atkins; S Bouralexis; D R Haynes; S E Graves; S M Geary; A Evdokiou; A C Zannettino; S Hay; D M Findlay Journal: Bone Date: 2001-04 Impact factor: 4.398
Authors: G Edel; Y Ueda; J Nakanishi; K H Brinker; A Roessner; S Blasius; T Vestring; H Müller-Miny; R Erlemann; P Wuisman Journal: Virchows Arch A Pathol Anat Histopathol Date: 1992
Authors: Daniele Santini; Gaia Schiavon; Bruno Vincenzi; Laura Gaeta; Francesco Pantano; Antonio Russo; Cinzia Ortega; Camillo Porta; Sara Galluzzo; Grazia Armento; Nicla La Verde; Cinzia Caroti; Isabelle Treilleux; Alessandro Ruggiero; Giuseppe Perrone; Raffaele Addeo; Philippe Clezardin; Andrea Onetti Muda; Giuseppe Tonini Journal: PLoS One Date: 2011-04-29 Impact factor: 3.240
Authors: Sergey Malchenko; Elisabeth A Seftor; Yuri Nikolsky; Susan L Hasegawa; Sean Kuo; Jeff W Stevens; Stas Poyarkov; Tatiana Nikolskaya; Tamara Kucaba; Min Wang; Hakim Abdulkawy; Thomas Casavant; Jose Morcuende; Joseph Buckwalter; Raymond Hohl; Barry Deyoung; Kemp Kernstine; Maria de Fatima Bonaldo; Mary J C Hendrix; Marcelo B Soares; Vera Maria F C Soares Journal: Sarcoma Date: 2012-02-16
Authors: Salvatore Romeo; Karoly Szuhai; Isao Nishimori; Marije Ijszenga; Pauline Wijers-Koster; Antonie H M Taminiau; Pancras C W Hogendoorn Journal: BMC Cancer Date: 2009-11-10 Impact factor: 4.430